Cost‐effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy in Denmark – Cost‐effectiveness analysis based on five randomised controlled trials

Background and Aims:  Budesonide/formoterol maintenance and reliever therapy (Symbicort SMART®) is an effective asthma‐management regime where patients use budesonide/formoterol both as maintenance treatment and as additional doses as needed to improve overall asthma control by reducing symptoms and exacerbations. The aim of this study was to determine the cost‐effectiveness of the Symbicort SMART® regime in Denmark vs higher dose inhaled corticosteroid (ICS) plus reliever medication, similar dose inhaled corticosteroid/long‐acting β2‐agonist (ICS/LABA) combination therapy plus reliever medication or higher dose of inhaled ICS/LABA combination therapy plus reliever medication.

[1]  Mark Sculpher,et al.  Transferability of economic evaluations across jurisdictions: ISPOR Good Research Practices Task Force report. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[2]  L. Boulet,et al.  Budesonide/formoterol maintenance and reliever therapy: impact on airway inflammation in asthma , 2008, European Respiratory Journal.

[3]  H. Magnussen,et al.  Budesonide/formoterol for maintenance and relief in uncontrolled asthma vs. high-dose salmeterol/fluticasone. , 2007, Respiratory medicine.

[4]  P. Kuna,et al.  Cost‐effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy , 2007, Allergy.

[5]  P. Kuna,et al.  Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations , 2007, International journal of clinical practice.

[6]  K. Rabe,et al.  Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study , 2006, The Lancet.

[7]  Michael Lundgren,et al.  Maintenance plus reliever budesonide/formoterol compared with a higher maintenance dose of budesonide/formoterol plus formoterol as reliever in asthma:an efficacy and cost-effectiveness study , 2006, Current medical research and opinion.

[8]  J. Molina,et al.  An international observational prospective study to determine the cost of asthma exacerbations (COAX). , 2006, Respiratory medicine.

[9]  K. Rabe,et al.  Budesonide/formoterol in a single inhaler for maintenance and relief in mild-to-moderate asthma: a randomized, double-blind trial. , 2006, Chest.

[10]  D. Stempel,et al.  Single-inhaler combination therapy for asthma: a review of cost effectiveness. , 2006, PharmacoEconomics.

[11]  D. Price,et al.  Budesonide/formoterol maintenance and reliever therapy: an effective asthma treatment option? , 2005, European Respiratory Journal.

[12]  H. Bisgaard,et al.  Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. , 2005, American journal of respiratory and critical care medicine.

[13]  M. Drummond,et al.  Collection of health-economic data alongside clinical trials: is there a future for piggyback evaluations? , 2005, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[14]  L. Boulet,et al.  Efficacy and safety of budesonide/formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma , 2004, Current medical research and opinion.

[15]  G. Nielsen,et al.  [Cost-of-illness of asthma in Denmark in the year 2000]. , 2003, Ugeskrift for laeger.

[16]  Jay K. Dow,et al.  The Bias Against New Innovations in Health Care: Value Uncertainty and Willingness to Pay , 2002, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[17]  A Tattersfield,et al.  Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. , 2001, American journal of respiratory and critical care medicine.

[18]  S. Shrewsbury,et al.  Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA) , 2000, BMJ : British Medical Journal.

[19]  J. FitzGerald,et al.  Effect of inhaled formoterol and budesonide on exacerbations of asthma. , 1998, The New England journal of medicine.

[20]  D. Postma,et al.  Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. , 1997, The New England journal of medicine.

[21]  R. Pauwels,et al.  GLOBAL STRATEGY FOR ASTHMA MANAGEMENT AND PREVENTION , 1996 .

[22]  A. Woolcock,et al.  Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. , 1996, American journal of respiratory and critical care medicine.

[23]  P. Ind,et al.  Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid , 1994, The Lancet.

[24]  A. Camm,et al.  DEGENERATION OF JUNCTIONAL TACHYCARDIA TO PRE-EXCITED ATRIAL FIBRILLATION AFTER INTRAVENOUS VERAPAMIL , 1989, The Lancet.